• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Septerna Inc.

    7/2/25 4:15:12 PM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SEPN alert in real time by email
    8-K
    false 0001984086 0001984086 2025-07-01 2025-07-01
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): July 1, 2025

     

     

    Septerna, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

     

    Delaware   001-42382   84-3891440
    (State or Other Jurisdiction
    of Incorporation)
     

    (Commission

    File Number)

      (IRS Employer
    Identification No.)

     

    250 East Grand Avenue    
    South San Francisco, California     94080
    (Address of Principal Executive Offices)     (Zip Code)

    Registrant’s Telephone Number, Including Area Code: 650 338-3533

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     


    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange
    on which registered

    Common Stock, par value $0.001 per share   SEPN   The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 8.01.

    Other Events.

    On July 1, 2025, the previously announced Collaboration and License Agreement, dated as of May 13, 2025 (the “Collaboration Agreement”), by and between Septerna, Inc. (the “Company”) and Novo Nordisk A/S, became effective following the early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.

    A summary of the terms of the Collaboration Agreement is set forth in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 14, 2025, which summary is qualified in its entirety by reference to the full text of the Collaboration Agreement, a copy of which the Company intends to file as an exhibit to its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025.


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

          Septerna, Inc.
    Date: July 2, 2025     By:  

    /s/ Jeffrey Finer, M.D., Ph.D.

          Jeffrey Finer, M.D., Ph.D.
          President and Chief Executive Officer
    Get the next $SEPN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SEPN

    DatePrice TargetRatingAnalyst
    6/23/2025$26.00Buy
    H.C. Wainwright
    2/18/2025$14.00Overweight → Equal Weight
    Wells Fargo
    11/19/2024$38.00Overweight
    Analyst
    11/19/2024Buy
    TD Cowen
    11/19/2024$43.00Overweight
    Wells Fargo
    11/19/2024$50.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $SEPN
    SEC Filings

    See more
    • SEC Form 8-K filed by Septerna Inc.

      8-K - Septerna, Inc. (0001984086) (Filer)

      7/2/25 4:15:12 PM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Septerna Inc.

      8-K - Septerna, Inc. (0001984086) (Filer)

      6/18/25 4:31:30 PM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Septerna Inc.

      SCHEDULE 13G/A - Septerna, Inc. (0001984086) (Subject)

      6/10/25 10:55:12 AM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SEPN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Septerna with a new price target

      H.C. Wainwright initiated coverage of Septerna with a rating of Buy and set a new price target of $26.00

      6/23/25 8:09:11 AM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Septerna downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Septerna from Overweight to Equal Weight and set a new price target of $14.00

      2/18/25 8:55:10 AM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Analyst initiated coverage on Septerna with a new price target

      Analyst initiated coverage of Septerna with a rating of Overweight and set a new price target of $38.00

      11/19/24 7:39:27 AM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SEPN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ezekowitz Alan bought $92,270 worth of shares (13,319 units at $6.93), increasing direct ownership by 13% to 117,420 units (SEC Form 4)

      4 - Septerna, Inc. (0001984086) (Issuer)

      3/10/25 4:18:19 PM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ezekowitz Alan bought $515,934 worth of shares (86,681 units at $5.95), increasing direct ownership by 498% to 104,101 units (SEC Form 4)

      4 - Septerna, Inc. (0001984086) (Issuer)

      3/6/25 9:02:51 PM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO and President Finer Jeffrey bought $96,961 worth of shares (17,000 units at $5.70), increasing direct ownership by 2% to 771,907 units (SEC Form 4)

      4 - Septerna, Inc. (0001984086) (Issuer)

      2/27/25 6:53:01 PM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care